Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público / Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia
Rev. méd. Chile
;
149(9): 1249-1257, sept. 2021. tab, ilus, graf
Article
Dans Espagnol
| LILACS
| ID: biblio-1389593
ABSTRACT
Background:
Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome.Aim:
To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material andMethods:
All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis.Results:
Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed.Conclusions:
The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Chromosome Philadelphie
/
Leucémie-lymphome lymphoblastique à précurseurs B
/
Leucémie-lymphome lymphoblastique à précurseurs B et T
Type d'étude:
Etude diagnostique
/
Guide de pratique
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adolescent
/
Adulte
/
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
2021
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Hospital del Salvador/CL
/
Universidad de los Andes/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS